Browsing Tag
Keymed Biosciences
4 posts
Gilead Sciences bets $2.2bn on immune reset with Ouro Medicines BCMAxCD3 bispecific acquisition
Gilead Sciences agrees to acquire Ouro Medicines for up to $2.175bn, adding BCMA T cell engager gamgertamig to its inflammation pipeline. Read the full strategic analysis.
Keymed Biosciences breaks new ground with CM518D1 IND approval for hard-to-treat gastrointestinal cancers
Discover how Keymed Biosciences' CM518D1 is advancing innovative treatment options for gastrointestinal cancers after IND approval!
InnoCare and KeyMed license CD20xCD3 antibody ICP-B02 to Prolium for global development
In a move poised to reshape the landscape of cancer and autoimmune treatments, InnoCare Pharma and KeyMed Biosciences…
Keymed Biosciences secures NMPA approval for Stapokibart in chronic rhinosinusitis treatment
Keymed Biosciences Inc. (HKEX: 02162) has received a significant regulatory endorsement as the National Medical Products Administration (NMPA)…